ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARHP Annual Meeting 2012

Abstract Number: 2137

Contribution of Disease Activity, Joint Damage and Comorbidity to Impairment (SOFI) and Disability (HAQ) in Rheumatoid Arthritis Patients Over 20 Years

Meliha C. Kapetanovic1, Elisabet Lindqvist2, Jan-Åke Nilsson3, Pierre Geborek4, Tore Saxne5 and Kerstin Eberhardt6, 1Dept of Clinical Sciences Lund, Section of Rheumatology, Lund University, Lund, Sweden, 2Department of Clinical Sciences Lund, Section of Rheumatology and Skåne University Hospital, Lund University, Lund, Sweden, 3Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, 4Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden, 5Section of Rheumatology, Deparment of Clinical Sciences, Lund, Lund University, Lund, Sweden, 6Department of Clinical Sciences Lund, Section of Rheumatology, Skåne University Hospital, Lund University, Lund, Sweden, Lund, Sweden

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARHP Annual Meeting 2012

Keywords: Comorbidity, Disability and rheumatoid arthritis (RA)

Session Information

Title: Rheumatoid Arthritis - Clinical Aspects III: Infections/Risk Factors for Incident Rheumatoid Arthritis/Metrology/Classification/Biomarkers/Predictors of Rheumatolid Arthritis Activity & Severity

Session Type: Abstract Submissions (ACR)

Background/Purpose: To study the contribution of disease activity, joint damage and co-morbidity on development of impairment measured by signals of functional impairment (SOFI) and disability measured by health assessment questionnaire (HAQ) in rheumatoid arthritis (RA) patients prospectively followed over 20 years after diagnosis.

Methods: 183 RA patients diagnosed between 1985 and 1989 were prospectively monitored over 20 years. There were 116 (63 %) women, mean (SD) age was 52 (12) years and symptom duration before inclusion was 11 (7) months. Disease activity was measured by 44-joint DAS, joint damage by Larsen score of radiographs of hands and feet, comorbidity by Charlson Comorbidity Index (17 diagnoses each weighted by mortality risk), impairment by SOFI (3-parts performance based index measuring hand, arm and leg function) and disability by HAQ. Two separate multiple regression models with SOFI and HAQ as outcome variables at 0, 5, 10, 15 and 20 year follow up were created.

Results: Altogether, disease activity, radiographic joint damage and co-morbidity explained 22-38% of SOFI and 14-38 % of HAQ (figure). For SOFI, DAS contributed with 2 -27 % with a peak at 5 years. Radiographic damage contributed increasingly (6-35%). For HAQ, DAS contributed significantly at all follow up times (7-28%), with a peak at 5 years whereas radiographic damage had minor contribution (0-10%). Comorbidity showed minor contribution both to SOFI and HAQ.

Conclusion: In the long-term perspective impairment is increasingly explained by radiographic damage, whereas disability is less well explained by RA related factors over time. Comorbidity contributed only to small extend to both impairment and disability.

Figure. Contribution of disease activity (DAS), joint damage (Larsen score) and comorbidity (Charlson comorbidity index) to impairment (SOFI) and disability (HAQ) in rheumatoid arthritis patients over 20 years


Disclosure:

M. C. Kapetanovic,
None;

E. Lindqvist,
None;

J. Nilsson,
None;

P. Geborek,
None;

T. Saxne,
None;

K. Eberhardt,
None.

ACR Meeting Abstracts - https://acrabstracts.org/abstract/contribution-of-disease-activity-joint-damage-and-comorbidity-to-impairment-sofi-and-disability-haq-in-rheumatoid-arthritis-patients-over-20-years/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology